▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

BostonGene Announces Partnership with Takeda to Evaluate Immunotherapies Using AI-Powered Molecular Profiling

BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immuno-oncology focused research studi...

Business Wire

Partnership to enable optimized patient selection and identification of key biomarkers in clinical trials

WALTHAM, Mass.: BostonGene, a leading provider of artificial intelligence (AI)-driven molecular and immune profiling solutions, announced that it will collaborate with Takeda on immuno-oncology focused research studies. This partnership aims to identify key molecular drivers and predictive markers for treatment efficacy and adverse effects with the primary goal of advancing clinical solutions and improving patient outcomes.

Takeda will leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials to enhance trial design, improve indication selection and identify biomarker signatures for response and toxicity. BostonGene will perform sophisticated multiomic analytics using proprietary computational platforms on clinical and laboratory data provided by Takeda. Additionally, BostonGene will conduct extensive bioinformatics analysis on flow cytometry, RNA-seq and proteomics data.

“We are pleased to enter this partnership with BostonGene, which will enable us to leverage cutting-edge technology to advance our oncology research and development,” said PK Morrow, MD, Head, Oncology Therapeutic Area Unit at Takeda. “Through this collaboration we look forward to utilizing data and AI to gain more insights into the biology and mechanisms of investigational therapies at the earliest stages. These data will help us to better understand their potential in certain patient populations and ultimately help advance oncology medicines for patients who need them.”

“BostonGene is excited to collaborate with Takeda,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “Our advanced multiomic analytics will significantly improve patient selection processes and pinpoint critical mechanistic signatures associated with response, driving forward the development of innovative treatments.”

About BostonGene Corporation
BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Dronus gets a strategic investment by Eni Next

Eni's VC company invest in the Italian drone company to develop new solutions for industrial plants monitoring

Technology Reply wins the 2024 Oracle Partner Awards - Europe South Innovation

Oracle recognizes Technology Reply’s ability to develop and deliver pioneering solutions through partnering with Oracle

25 Italian Startups Will Be Present at Expand North Star 2024

Scheduled for October, the world's largest startup event will bring together more than 2,000 exhibitors in Dubai, UAE

Most read

24 Promising Korean Tech Companies at TechCrunch Disrupt 2024

TechCrunch Disrupt 2024 will feature cutting-edge technology from 24 tech startups from South Korea. The Korea Pavilion is presented by Korea Trade-Investment…

Audit & Beyond Hosts Record Number of Attendees, Includes Launch of Powerful…

2024 AUDIT & BEYOND CONFERENCE — AuditBoard, the leading cloud-based platform transforming audit, risk, compliance, and ESG management, wrapped up…

University of Phoenix Launches New Career-Focused Skill Pathways in Practical…

In response to the growing demand for AI skills in the workforce, University of Phoenix is excited to announce the launch of new career-focused skill…

$16.4 Billion AI in Wound Care Market Industry Trends and Global Forecasts,…

The "AI in Wound Care Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Wound, Type of Acute Wound, Type of Chronic Wound,…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!